#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer’s Disease"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Esther Wollert"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/209a3048003c8d92394e6b64778447bd996a21e6/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET STATEMENT_GROUP = "Esther"

# Add statements below this comment

SET Citation = {"PubMed","J Med Chem. 2018 Nov 30. doi: 10.1021/acs.jmedchem.8b01530.","30444369"}

SET Evidence ="Only five drugs
(Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are
cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is
a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents
have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the
progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive
impairment and help to maintain global function, delaying the need for patient palliative care by only a few month"
SET MeSHDisease = "Alzheimer Disease"
#improved in contrast to disease
a(CHEBI:tacrine) -> bp(GO:cognition)
a(CHEBI:donepezil) -> bp(GO:cognition)
a(CHEBI:rivastigmine) -> bp(GO:cognition)
a(CHEBI:galanthamine) -> bp(GO:cognition)
a(CHEBI:memantine) -> bp(GO:cognition)
UNSET MeSHDisease
a(CHEBI:tacrine) -| act(p(FPLX:Cholinesterase))
a(CHEBI:donepezil) -| act(p(FPLX:Cholinesterase))
a(CHEBI:rivastigmine) -| act(p(FPLX:Cholinesterase))
a(CHEBI:galanthamine) -| act(p(FPLX:Cholinesterase))
a(CHEBI:memantine) -| act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))

SET Evidence = "Genetics have a role to play within AD; patients with a mutation in Amyloid Precursor Protein
(APP), which results in overproduction of Aβ, will experience early onset AD. 36  Patients with a mutation
in Apolipoprotein E4 (APOE4), which affects the clearance of Aβ, will experience late onset AD."
g(HGNC:APP, var("?")) -> path(MESH:"Alzheimer Disease")
g(HGNC:APP, var("?")) -> p(HGNC:MAPT)
g(HBP:"APOE e4") -> path(MESH:"Alzheimer Disease")
g(HBP:"APOE e4") -| deg(p(HGNC:APP))

SET Evidence = " In
addition, several other gene mutations have been discovered such as Presenilin-1 and Presenilin-2
mutations, which increase the risk for developing AD. 38  "
g(HGNC:PSEN1, var("?")) -> path(MESH:"Alzheimer Disease")
g(HGNC:PSEN2, var("?")) -> path(MESH:"Alzheimer Disease")

SET Evidence = "The formation of Aβ starts by a transmembrane protein,
APP (695 to 770 amino acids in length), which is sequentially cleaved by the aspartate proteases β-
and  γ-secretase,  that  leads  to  the  formation  of  Aβ  peptide  (1-42)  and  a  degenerated  C-terminus. "
p(HGNC:BACE1) -> rxn(reactants(p(HGNC:APP)),products(a(CHEBI:"amyloid-beta polypeptide 42"), p(HBP:"APP C-terminally truncated carboxyl-terminal fragments")))
p(FPLX:"Gamma_secretase") -> rxn(reactants(p(HGNC:APP)),products(a(CHEBI:"amyloid-beta polypeptide 42"), p(HBP:"APP C-terminally truncated carboxyl-terminal fragments")))

SET Evidence = " Mitochondrial  dysfunction  is  the  hallmark  of  Aβ-induced
toxicity. 50-52  "
a(HBP:"amyloid-beta aggregates") -> path(HBP:"mitochondrial dysfunction")

SET Evidence = "Accumulation of Aβ has also been associated with a decrease in the activity of
cytochrome c oxidase, the terminal enzyme in the electron transport chain. "
a(HBP:"amyloid-beta aggregates") -| act(p(FPLX:COX))

SET Evidence = " Binding of Aβ to ABAD
has been implicated in the development of AD, recent studies detected elevated ABAD levels in the
regions of the hippocampus and cerebral cortex which are generally affected by AD pathology"
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> path(MESH:"Alzheimer Disease")
SET MeSHAnatomy = {"Cerebral Cortex","Hippocampus"}
path(MESH:"Alzheimer Disease") pos p(HGNC:HSD17B10)
UNSET MeSHAnatomy

SET Evidence = "The  enzyme  is  also  required  for  the
catabolism of isoleucine, in which it catalyzes the conversion of 2-methyl-3-hydroxybutyryl-coA (MHB)
to 2-methyl-acetoacetyl-coA. 72  "
act(p(HGNC:HSD17B10)) -> rxn(reactants(a(PUBCHEM:"440326")),products(a(PUBCHEM:"193425")))

SET Evidence = "The enzyme catalyzes the third step of mitochondrial
oxidation, converting  L -3-hydroxyacyl-CoA in the presence of NAD +  to 3-ketoacyl-CoA, NADH, and H + ."
act(p(HGNC:HSD17B10)) -> rxn(reactants(a(PUBCHEM:"9543037"),a(CHEBI:"NAD(+)")),products(a(CHEBI:"3-oxo-fatty acyl-CoA(4-)"),a(CHEBI:NADH),a(PUBCHEM:"1038")))

SET Evidence ="The  oxidation  of  3-adiol  to  5-dihydrotestosterone  in
androgen  metabolism  is  catalyzed  by  ABAD  and  it  converts  17β-estradiol  to  estrone  in  estrogen
metabolism."
act(p(HGNC:HSD17B10)) -> rxn(reactants(a(PUBCHEM:"15818")),products(a(PUBCHEM:"10635")))
act(p(HGNC:HSD17B10)) -> rxn(reactants(a(PUBCHEM:"5757")),products(a(PUBCHEM:"5870")))

SET Evidence = "Moreover,  function  of  ABAD  has  also  been  associated  with  GABA A   receptors,  as  it  catalyzes  the
oxidation of the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone, both of which
are positive modulators of GABA A  receptors in the brain."
act(p(HGNC:HSD17B10)) -- p(FPLX:GABR)

SET Evidence = " For example, estradiol
can reduce the generation of Aβ by altering the metabolism of APP and disrupting it’s trafficking."
a(PUBCHEM:"5757") -| a(HBP:"amyloid-beta aggregates")

SET Evidence = "Moreover,  estradiol  has  been  shown  to  inhibit  tau  hyperphosphorylation  and  can  also  modulate
glycogen  synthase  kinase-3β  (GSK-3β)  activity,  a  kinase  that  is  involved  in  tau  phosphorylation.
Estradiol  deactivates  GSK-3β  by  inducing  its  phosphorylation,  thereafter  reducing  tau
phosphorylation. "
a(PUBCHEM:"5757") -| p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))
a(PUBCHEM:"5757") -| act(p(HGNC:GSK3B))
a(PUBCHEM:"5757") -> p(HGNC:GSK3B, pmod(Ph))
act(p(HGNC:GSK3B)) -> p(HGNC:MAPT, pmod(Ph))

SET Evidence = " In mechanistic studies, it was proposed that methylene blue inhibits the
Aβ-ABAD interaction and decreases mitochondrial dysfunction by decreasing the expression of ABAD
levels, in addition to decreasing Aβ levels."
a(CHEBI:"methylene blue") -| complex(p(HGNC:HSD17B10),p(HGNC:APP))
a(CHEBI:"methylene blue") -| path(HBP:"mitochondrial dysfunction")
a(CHEBI:"methylene blue") -| p(HGNC:HSD17B10)
a(CHEBI:"methylene blue") -| a(HBP:"amyloid-beta aggregates")

SET Evidence = " Neurons from these animals exhibited increased oxidative stress, increased
generation of ROS, DNA fragmentation, neuronal apoptosis, and impairment in learning, compared to
single-transgenic mAPP mice."
SET MeSHAnatomy = "Neurons"
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> bp(GO:"response to oxidative stress")
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> a(CHEBI:"reactive oxygen species")
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> bp(GO:"apoptotic DNA fragmentation")
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> bp(GO:"neuron death")
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -| bp(GO:learning)

SET Evidence = "In another study, neurons from Tg mAPP/ABAD mice were shown to
exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of
mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from
mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death."
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -| act(p(FPLX:COX))
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> a(CHEBI:"reactive oxygen species")
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -| bp(GO:"regulation of mitochondrial membrane potential")
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -| a(CHEBI:ATP)
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> act(p(HGNC:CASP3))
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -> bp(GO:"apoptotic process")

SET Evidence = "However, it is well established that Aβ binding to ABAD induces a conformational change in the enzyme
that  prevents  the  binding  of  NAD + ,  preventing  the  enzyme  performing  its  role  in  the  oxidation  of
substrates, leading to changes in mitochondrial membrane permeability, which in turn has deleterious
effects  on  mitochondrial  enzymes."
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -| complex(p(HGNC:HSD17B10),a(CHEBI:"NAD(+)"))
complex(p(HGNC:HSD17B10),p(HGNC:APP)) -| act(p(HGNC:HSD17B10))

SET Evidence = "  It  enhances  the  expression  of  anti-
apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic
factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect
neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and
glutathione peroxidase. 101  "
a(PUBCHEM:"5757") -> p(HGNC:BCL2)
a(PUBCHEM:"5757") -> p(HGNC:BCL2L1)
a(PUBCHEM:"5757") -| p(HGNC:BCL2L11)
p(HGNC:BCL2) -| bp(GO:"apoptotic process")
p(HGNC:BCL2L1) -| bp(GO:"apoptotic process")
p(HGNC:BCL2L11) -> bp(GO:"apoptotic process")
a(PUBCHEM:"5757") -> p(HGNC:SOD2)
a(PUBCHEM:"5757") -> p(FPLX:GPX)

SET Evidence = "The first, peroxiredoxin-2 (Prdx-2), functions as an antioxidant and has been
shown to  be inactivated  in  AD."
path(MESH:"Alzheimer Disease") neg act(p(HGNC:PRDX2))

SET Evidence = "In  transgenic  AD  mice  and  the  post-mortem  human  brain  of  AD
patients, the expression of Prdx-2 is shown to be elevated, due to the attempted protection of neurons
from Aβ-induced toxicity."
path(MESH:"Alzheimer Disease") pos p(HGNC:PRDX2)

SET Evidence = " Inactivation of Prdx-2 is controlled by a kinase that has been shown to be
elevated in AD, CDK5, 107, 108  which phosphorylates Thr 89  and results in deactivation of Prdx-2."
path(MESH:"Alzheimer Disease") pos p(HGNC:CDK5)
p(HGNC:CDK5) -> p(HGNC:PRDX2, pmod(Ph,Thr,89))
p(HGNC:PRDX2, pmod(Ph,Thr,89)) -| act(p(HGNC:PRDX2))

SET Evidence = "The second ABAD-related protein, endophilin-1 (Ep-1), is a member of a family of proteins that
are responsible for synaptic vesicle endocytosis, mitochondrial function, and receptor trafficking. 110  This
family of proteins has been implicated in a number of neurodegenerative diseases, 111  including in AD
where it is overexpressed"
p(HGNC:SH3GL2) -> bp(GO:"synaptic vesicle endocytosis")
path(MESH:"Alzheimer Disease") pos p(HGNC:SH3GL2)

SET Evidence = " This results in the activation of mitogen-activated
protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually
leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream
effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth,
mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1"
p(HGNC:SH3GL2) -> act(p(HGNC:MAP3K1))
p(HGNC:SH3GL2) -- bp(GO:"neuron projection development")
p(HGNC:SH3GL2) -- bp(GO:"regulation of synaptic plasticity")
p(HGNC:SH3GL2) -- bp(GO:"neuron death")

SET Evidence = "A potent ABAD inhibitor,
AG18051 (1), containing a pyrazolo[3,4-d] pyrimidine-4(1H)-thione backbone (IC 50  = 92 nM) has been
reported. "
#22174920
a(HBP:"AG18051") -| act(p(HGNC:HSD17B10))

SET Evidence = " Moreover, it has been shown
to ameliorate Aβ-induced toxicity at the cellular level. 7"
a(HBP:"AG18051") -| act(a(HBP:"amyloid-beta aggregates"))

SET Evidence = "Interestingly, during the search for inhibitors of 17β-HSD isoforms for the treatment of estrogen-
related diseases, 127  Ayan et.al identified the steroidal compound RM-532-46 (8) as a reversible ABAD
inhibitor (IC 50  = 0.55 M)."
#22674910
a(HBP:"RM-532-46") -| act(p(HGNC:HSD17B10))

SET Evidence = "Frentizole,  an  FDA  approved  immunosuppressant  drug,  was  identified  as  an  Aβ-ABAD
interaction  inhibitor  (IC 50  =  200  M)  using  an  ELISA-based  screening  assay."
a(PUBCHEM:"33334") -| complex(p(HGNC:HSD17B10),p(HGNC:APP))

SET Evidence = " Isoforms  of  CK1  are  responsible  for  tau
phosphorylation. 129   The  enzyme  can  modulate  the  activity  of  γ-secretase  and  consequently  the
production of Aβ."
p(HGNC:CSNK1A1) -> p(HGNC:MAPT, pmod(Ph))
p(HGNC:CSNK1A1) reg act(p(FPLX:"Gamma_secretase"))
p(HGNC:CSNK1A1) -- a(HBP:"amyloid-beta aggregates")

SET Evidence = "Screening previously synthesized frentizole derivatives for their efficiency to inhibit
CK1 activity as well as ABAD, identified compound 13 which possessed an ABAD IC 50  = 1.67 µM, the
most  potent  inhibitor  of  this  chemotype  identified  to  date."
a(PUBCHEM:"33334") -| act(p(HGNC:CSNK1A1))

SET Evidence = "The frentizole scaffold has been combined with the known monoamine oxidase inhibitor (MAOI)
ladostigil to identify a molecule that has a dual effect; inhibiting both ABAD and MAO. A library of
synthesized derivatives demonstrated that the most potent inhibitor for MAO (IC 50  = 6.34 µM) lacked
ABAD inhibition activity."
a(PUBCHEM:"208907") -| act(p(HGNC:MAOA))
a(PUBCHEM:"208907") cnc act(p(HGNC:CSNK1A1))
